SCHEMBL6946687

SCHEMBL6946687

Cc1ccccc1SC=CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.42
ALDH1A1 P00352 5/20 0.42
LMNA P02545 4/20 0.42
MAPT P10636 4/20 0.42
KMT2A Q03164 2/20 0.42
NFKB1 P19838 2/20 0.42
MEN1 O00255 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
GAA P10253 1/20 0.41
HPGD P15428 3/20 0.41
HTT P42858 3/20 0.41
PLIN1 O60240 1/20 0.41
PLIN5 Q00G26 1/20 0.41
ABHD5 Q8WTS1 1/20 0.41
MAPK1 P28482 1/20 0.40
MDM2 Q00987 1/20 0.40
HDAC3 O15379 1/20 0.39
TNKS O95271 1/20 0.39
HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946681 1.00 NPSR1 (0.42) NPSR1ALDH1A1LMNAMAPTKMT2A
SCHEMBL7464335 0.84 MAPT (0.38) NPSR1ALDH1A1LMNAMAPTKMT2A
Maleic Acid SCHEMBL31082131 0.81 GAA (0.47) NPSR1ALDH1A1LMNAMAPTKMT2A
Fumaric Acid SCHEMBL31082155 0.81 GAA (0.47) NPSR1ALDH1A1LMNAMAPTKMT2A
SCHEMBL4649040 0.80 MMP1 (0.49) NPSR1ALDH1A1MAPTKMT2ANFKB1
SCHEMBL4649042 0.80 MMP1 (0.49) NPSR1ALDH1A1MAPTKMT2ANFKB1
SCHEMBL4647175 0.78 NPSR1 (0.40) NPSR1ALDH1A1LMNAMAPTKMT2A
SCHEMBL6942134 0.77 SMN1; SMN2 (0.49) ALDH1A1LMNAMAPTKMT2AGAA
SCHEMBL6942137 0.77 SMN1; SMN2 (0.49) ALDH1A1LMNAMAPTKMT2AGAA
O-Xylene SCHEMBL6232604 0.75 GAA (0.56) NPSR1ALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642246-B1 Potent ligands for nicotinic acetylcholine receptors (nAChRs). Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's ASTRAZENECA AB (SE) 2003-11-04 US disclosed
EP-1235826-B1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2003-09-03 EP disclosed
EP-1235826-A1 QUINUCLIDINE ACRYLAMIDES AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2001029034-A1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2001-04-26 WO disclosed